AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15574604 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (1 g applied for 30 minutes before vaccination)
Number of subjects: 120
Study 15574604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g applied for 30 minutes before vaccination)
Number of subjects: 120
Study 10809936 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rivastigmine (6-12 mg/day)
Number of subjects: 699
Study 10809936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study 10809936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rivastigmine (1-4 mg/day)
Number of subjects: 699
Study 8975854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold temperature (8-10 degrees C)
Number of subjects: 116
Study 8975854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid temperature (32 degrees C)
Number of subjects: 116
Study 8975854 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm temperature (37 degrees C)
Number of subjects: 116
Study 1472143 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg once daily
Number of subjects: 105
Study 1472143 — intervention group
Group type: COMPARATOR
Intervention: terfenadine 120 mg once daily
Number of subjects: 105
Study 1472143 — intervention group
Group type: EXPERIMENTAL
Intervention: nasal peak flow
Number of subjects: 105
Study 6708399 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg fenoterol powder
Number of subjects: 10
Study 6708399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31562911 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 taken just before operation and twice daily up to 15 total doses
Number of subjects: 135
Study 31562911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 31562911 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3
Number of subjects: 135
Study 28779655 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d vitamin D
Number of subjects: 121
Study 28779655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D
Number of subjects: 121
Study 28779655 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d vitamin D
Number of subjects: 121
Study 25323601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral fractures
Number of subjects: 3673
Study 25323601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density (measured in Hounsfield Units)
Number of subjects: 3673
Study 23229869 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg low-dose intrathecal bupivacaine
Number of subjects: 49
Study 23229869 — intervention group
Group type: COMPARATOR
Intervention: 10 mg standard-dose intrathecal bupivacaine
Number of subjects: 49
Study 21744954 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions and objects in English learners at 18 months
Number of subjects: 128
Study 21744954 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions and objects in English learners at 14 months
Number of subjects: 128
Study 21744954 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions in Mandarin learners at 14 months
Number of subjects: 128
Study 21744954 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions in Mandarin learners at 18 months
Number of subjects: 128
Study 19084838 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 70
Study 16707915 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 15
Study 16707915 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 15101864 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-containing prime (Group B, n = 18)
Number of subjects: 36
Study 15101864 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid prime (Group C, n = 18)
Number of subjects: 36
Study 10672630 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (equal to baseline daily caffeine consumption)
Number of subjects: 10
Study 10672630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during caffeine-free diet)
Number of subjects: 10
Study 9327317 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg orally before surgery and once daily postoperatively
Number of subjects: 30
Study 9327317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1304204 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous curvilinear capsulorhexis (CCC)
Number of subjects: 40
Study 1304204 — intervention group
Group type: COMPARATOR
Intervention: Can opener
Number of subjects: 40
Study 1304204 — intervention group
Group type: COMPARATOR
Intervention: Linear capsulotomy
Number of subjects: 40
Study 1304204 — intervention group
Group type: COMPARATOR
Intervention: Capsulopuncture ('postage stamp')
Number of subjects: 40
Study 4003987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant interferon alpha‐2 at dosages of 10 to 50 MU/d
Number of subjects: 33
Study 4003987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interferon alpha‐2 at dosages of 10 to 50 MU/d
Number of subjects: 33
Study 3067408 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate standard tablets (nitrosorbide-NS) at a dose of 10 mg per os
Number of subjects: 28
Study 3067408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual NS administration
Number of subjects: 28
Study 3067408 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate prolonged action isomac-retard containing 40 mg
Number of subjects: 28
Study 3067408 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrosorbilong (DNL) for gingival application
Number of subjects: 28
Study 3067408 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased NS dose per os
Number of subjects: 28
Study 29179016 — intervention group
Group type: EXPERIMENTAL
Intervention: Group family-based cognitive behavioral therapy (GF-CBT)
Number of subjects: 85
Study 25743819 — intervention group
Group type: EXPERIMENTAL
Intervention: EAAL treatment group
Number of subjects: 32
Study 25743819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 23054940 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (increased minutes of physical activity over 12 months)
Number of subjects: 64
Study 23054940 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cardiovascular fitness and more physical activity (self-reported)
Number of subjects: 64
Study 21915515 — intervention group
Group type: EXPERIMENTAL
Intervention: FL‐ Fluorniz (n=24)
Number of subjects: 36
Study 21915515 — intervention group
Group type: EXPERIMENTAL
Intervention: DUO ‐ Duofluorid XII (n=22)
Number of subjects: 36
Study 21915515 — intervention group
Group type: EXPERIMENTAL
Intervention: DF ‐ Durafluor (n=21)
Number of subjects: 36
Study 21915515 — intervention group
Group type: EXPERIMENTAL
Intervention: All varnishes
Number of subjects: 36
Study 18174447 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced therapy (mCIT)
Number of subjects: 35
Study 18174447 — intervention group
Group type: COMPARATOR
Intervention: Time-matched exercise program
Number of subjects: 35
Study 18174447 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control regimen
Number of subjects: 35
Study 16340597 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (5 U)
Number of subjects: 31
Study 16340597 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 31
Study 14626260 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 14626260 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study 10907099 — intervention group
Group type: EXPERIMENTAL
Intervention: High intrinsic religious orientation with threatening feedback on important behavior
Number of subjects: 0
Study 10907099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intrinsic religious orientation with threatening feedback on important behavior
Number of subjects: 0
Study 10907099 — intervention group
Group type: EXPERIMENTAL
Intervention: High intrinsic religious orientation with bolstering feedback
Number of subjects: 0
Study 10907099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intrinsic religious orientation with bolstering feedback
Number of subjects: 0
Study 10907099 — intervention group
Group type: EXPERIMENTAL
Intervention: High intrinsic religious orientation with threatening feedback on unimportant behavior
Number of subjects: 0
Study 10907099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intrinsic religious orientation with threatening feedback on unimportant behavior
Number of subjects: 0
Study 8850397 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (30 ng/kg/min)
Number of subjects: 19
Study 8850397 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 19
Study 1320916 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 340
Study 1320916 — intervention group
Group type: COMPARATOR
Intervention: Alizapride (12 mg/kg) plus Dexamethasone (8 mg)
Number of subjects: 340
Study 1320916 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (7 mg/kg) plus Dexamethasone (12 mg)
Number of subjects: 340
Study 6375273 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin 5000 IU every 12 hours
Number of subjects: 64
Study 6375273 — intervention group
Group type: COMPARATOR
Intervention: TED stocking (Kendall Co.)
Number of subjects: 64
Study 30415432 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART irrespective of CD4 count offered from the trial-start in 2014
Number of subjects: 0
Study 29686818 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS‐EP (specific exercise programme based on moderate aerobic workout and isometric contractions)
Number of subjects: 38
Study 29686818 — intervention group
Group type: COMPARATOR
Intervention: Standard neuromotor rehabilitation treatment
Number of subjects: 38
Study 26725544 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 590
Study 26725544 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 590
Study 26725544 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 5 mg
Number of subjects: 590
Study 26725544 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 590
Study 26725544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 24647464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participants (n = 1325)
Number of subjects: 1325
Study 24647464 — intervention group
Group type: COMPARATOR
Intervention: General population patients (n = 1056)
Number of subjects: 1325
Study 22710266 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal of near‐maximal stroke volume guided by oesophageal Doppler (D group)
Number of subjects: 150
Study 22710266 — intervention group
Group type: COMPARATOR
Intervention: Goal of zero balance and normal bodyweight (Z group)
Number of subjects: 150
Study 22710266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (D and Z)
Number of subjects: 150
Study 20032478 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg/d
Number of subjects: 93
Study 20032478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 19127916 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 2
Study 19127916 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 2
Study 15795570 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric Gamma nail
Number of subjects: 210
Study 15795570 — intervention group
Group type: COMPARATOR
Intervention: Compression hip screw
Number of subjects: 210
Study 11552015 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU IFN-alpha2a ingested on alternate days for 9 months
Number of subjects: 30
Study 11552015 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU IFN-alpha2a ingested on alternate days for 9 months
Number of subjects: 30
Study 11552015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9661845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 20) with marked external tibial torsion, TFA > or = 20 degrees
Number of subjects: 25
Study 9661845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (n = 20) with TFA between 10 and 20 degrees
Number of subjects: 25
Study 9661845 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 normal limbs with TFA = 10 degrees)
Number of subjects: 25
Study 9661845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I limbs compared to Group II limbs
Number of subjects: 25
Study 9661845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I limbs
Number of subjects: 25
Study 9661845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II limbs
Number of subjects: 25
Study 8057631 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-compliance touch
Number of subjects: 198
Study 8057631 — intervention group
Group type: COMPARATOR
Intervention: Nontouched subjects
Number of subjects: 198
Study 3185464 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (hypnotic)
Number of subjects: 12
Study 3185464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31808520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation for persistent AF
Number of subjects: 609
Study 30715535 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg Se from SY
Number of subjects: 768
Study 30715535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg Se from SY
Number of subjects: 768
Study 30715535 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg Se from SY
Number of subjects: 768
Study 30715535 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg Se from SY (basal diet)
Number of subjects: 768
Study 27838474 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized AHFS treatments (specific treatments not detailed)
Number of subjects: 0
Study 27838474 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with intravenous diuretics (control group)
Number of subjects: 0
Study 26119273 — intervention group
Group type: COMPARATOR
Intervention: ICD‐9 codes for mortality model
Number of subjects: 244704
Study 26119273 — intervention group
Group type: COMPARATOR
Intervention: ICD‐9 codes for hospital length of stay (HLOS) model
Number of subjects: 244704
Study 26119273 — intervention group
Group type: COMPARATOR
Intervention: ICD‐9 codes for intensive care unit length of stay (ILOS) model
Number of subjects: 244704
Study 23612942 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based HIV prevention intervention
Number of subjects: 728
Study 21500574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 72
Study 21500574 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 72
Study 21500574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 19681773 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger video laryngoscope
Number of subjects: 8
Study 19681773 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 8
Study 17207684 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural control training with external focus of attention
Number of subjects: 40
Study 17207684 — intervention group
Group type: COMPARATOR
Intervention: Postural control training with internal focus of attention
Number of subjects: 40
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 15 mg
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 35 mg
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 75 mg
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 150 mg
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 300 mg
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 35 mg repeated doses
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 75 mg repeated doses
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: A6 150 mg repeated doses
Number of subjects: 26
Study 15176647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal amphotericine B + oral itraconazole
Number of subjects: 88
Study 11533546 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluconazole + oral itraconazole
Number of subjects: 88
Study 9683361 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg/day
Number of subjects: 66
Study 9683361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7851235 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood glucose monitoring (CBGM) using AccuChek II blood glucose meter
Number of subjects: 80
Study 7851235 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood glucose monitoring (CBGM) using visual and manual interpretation
Number of subjects: 80
Study 7851235 — intervention group
Group type: COMPARATOR
Intervention: Capillary blood glucose monitoring (CBGM)
Number of subjects: 80
Study 3141293 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 14
Study 3141293 — intervention group
Group type: COMPARATOR
Intervention: LCT exclusively
Number of subjects: 14
Study 31595803 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication usage recorded as a treatment for nausea AEs (76% of cases)
Number of subjects: 101
Study 31595803 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusions provided for thrombocytopenia AEs (24% of cases)
Number of subjects: 101
Study 31595803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea AEs
Number of subjects: 101
Study 31595803 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia AEs
Number of subjects: 101
Study 29578944 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05089771 150 mg twice daily
Number of subjects: 135
Study 29578944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 135
Study 29578944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 28424870 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent high-intensity interval training (CT)
Number of subjects: 16
Study 28424870 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 16
Study 26040644 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient-held portable health file (PHF) added to usual care
Number of subjects: 792
Study 26040644 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper patient-held portable health file (PHF) added to usual care
Number of subjects: 792
Study 26040644 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (no PHF)
Number of subjects: 792
Study 26040644 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 792
Study 22983355 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)FDG PET-guided rTMS
Number of subjects: 15
Study 22983355 — intervention group
Group type: COMPARATOR
Intervention: Standard anatomically guided rTMS
Number of subjects: 15
Study 22983355 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 23511042 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga with counselling
Number of subjects: 60
Study 23511042 — intervention group
Group type: COMPARATOR
Intervention: Only counselling
Number of subjects: 60
Study 20128424 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 30
Study 20128424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16703624 — intervention group
Group type: COMPARATOR
Intervention: 30% perioperative oxygen
Number of subjects: 45
Study 16703624 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% perioperative oxygen
Number of subjects: 45
Study 15657474 — intervention group
Group type: COMPARATOR
Intervention: CAF (5 mg/kg)
Number of subjects: 13
Study 15657474 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (3 mg/kg)
Number of subjects: 13
Study 15657474 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (7 mg/kg)
Number of subjects: 13
Study 11377115 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening with or without DRE
Number of subjects: 0
Study 11377115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8913208 — intervention group
Group type: COMPARATOR
Intervention: Volume control ventilation with a square flow waveform
Number of subjects: 25
Study 8913208 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume control with a decelerating flow waveform
Number of subjects: 25
Study 8913208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure control ventilation
Number of subjects: 25
Study 8913208 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume control ventilation with a decelerating flow waveform
Number of subjects: 25
Study 2082718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (20 mg/day during the last 12 days of the menstrual cycle)
Number of subjects: 22
Study 2082718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 299221 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-Immunotherapy consisting of 5-Fluorouracil and CCNU and Corynebacterium parvum administered intermittently for one year.
Number of subjects: 0
Study 299221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31782768 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 × 105 PfSPZ Vaccine
Number of subjects: 22
Study 31782768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 × 106 PfSPZ Vaccine
Number of subjects: 22
Study 31782768 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study 31505943 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized insole with metatarsal and arch support
Number of subjects: 72